IDH1 and central nervous system cancer: Patients with Grade III gliomas lacking 1p/19q codeletion and harboring IDH mutations have significantly prolonged progression-free survival (PFS) and overall survival (OS), with similar trends observed in secondary high-grade gliomas (HGGs).28 A comprehensive meta-analysis further validated the strong correlation between IDH1/2 mutations and improved survival in patients with GBM.29